title: The role of rHuEpo in low-risk myelodysplastic syndrome patients.
abstract: Myelodysplastic syndromes (MDS) are clonal disorders of the haemopoietic stem cell characterized by peripheral cytopenias that are the result of abnormal haemopoietic differentiation and maturation. Approximately 90% of MDS patients present with anemia at the beginning or during the course of the disease and often require transfusions. The rationale for treating anemic MDS patients with recombinant human erythropoietin (rHuEpo), alone or in combination with other growth factors, is based on the possibility of overcoming the defective proliferation and maturation of erythroid precursors through the inhibition of bone marrow apoptosis, the enhancement of the differentiation of preleukemic progenitor cells or the stimulation of the growth of residual normal haematopoietic cells. Clinical trails have shown that rHuEpo, alone or in combination with recombinant human granulocyte colony-stimulating factor, is a useful drug for the treatment of anemia in low-risk MDS patients, and the same trials have identified patients who are more likely to respond to maximize benefits, to minimize adverse effects, and to avoid misuse or abuse. However, further research is required to determine whether this treatment has any real impact on quality of life and on life expectancy, thus allowing recommendations to be made about rHuEpo use in MDS patients with a degree of certainty.
authors: Hematology Section, Department of Biomedical Sciences, University of Ferrara, Italy. rglgmt@unife.it
authors: Gian Matteo
authors: GM
authors: Rigolin
authors: Gianluigi
authors: G
authors: Castoldi
mesh_terms: D000465:Algorithms; D017209:Apoptosis; D049109:Cell Proliferation; D004921:Erythropoietin / Q000627:therapeutic use*; D005060:Europe; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D017408:Guidelines as Topic; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D013234:Stem Cells / Q000166:cytology; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor